© 2020 MJH Life Sciences™ and Cancer Network. All rights reserved.
Author | Kristie L. Kahl
Articles
FDA Approves Nivolumab Plus Ipilimumab for Previously Untreated Unresectable Malignant Pleural Mesothelioma
October 02, 2020
The agency approved the first and only immunotherapy treatment as a first-line therapy for adult patients with unresectable malignant pleural mesothelioma.
Cabozantinib Plus Atezolizumab Shows Promising Clinical Activity in Advanced Clear Cell Renal Cell Carcinoma
September 21, 2020
“The combination of cabozantinib and atezolizumab demonstrated encouraging clinical activity in previously untreated patients with advanced ccRCC,” said investigator Sumanta Kumar Pal, MD.
AMG 160 Appears Safe with Preliminary Efficacy in mCRPC
September 21, 2020
Treatment with a novel BiTE® immuno-oncology therapy showed a manageable safety profile with preliminary efficacy in patients with metastatic castration-resistant prostate cancer.
Olaparib Significantly Improves OS in mCRPC Subgroup
September 20, 2020
The PARP inhibitor reduced the risk for death by 31% in men with metastatic castration-resistant prostate cancer, compared with enzalutamide or abiraterone plus prednisone.